drugset

drugset / Trial / NCT02367196

A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers

NCT02367196 ↗

Phase 1 Completed 60 enrolled Celgene Corporation

NaParallel-groupOpen-labelTreatment

Summary

CC-90002-ST -001 is an open-label, Phase 1, dose escalation clinical study in subjects with advanced, refractory solid and hematologic cancers.

Timeline

Start: 2015-03-12
Primary completion: 2020-12-24
Completion: 2020-12-24

Publications

Narla RK, Modi H, Bauer D, Abbasian M, Leisten J, Piccotti JR, Kopytek S, Eckelman BP, Deveraux Q, Timmer J, Zhu D, Wong L, Escoubet L, Raymon HK, Hariharan K. Modulation of CD47-SIRPalpha innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody. Cancer Immunol Immunother. 2022 Feb;71(2):473-489. doi: 10.1007/s00262-021-03010-6. Epub 2021 Jul 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CC-90002	Monoclonal antibody	—	Intravenous
Background	Rituximab	Monoclonal antibody	—	Intravenous

Indications